利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.049 秒)

    Drug cores for sustained release of therapeutic agents
    1.
    发明授权
    Drug cores for sustained release of therapeutic agents 有权
    用于持续释放治疗剂的药物核心

    公开(公告)号：US08628792B2

    公开(公告)日：2014-01-14

    申请号：US13367823

    申请日：2012-02-07

    申请人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene De Juan, Jr. ,  Cary J. Reich

    发明人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene De Juan, Jr. ,  Cary J. Reich

    IPC分类号： A61F2/00 ,  B28B11/12

    CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F9/00772 ,  A61F2230/0069 ,  A61F2250/0067 ,  A61K31/5575 ,  A61K47/34 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/602 ,  A61L2300/802 ,  Y02A50/395

    摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

    摘要翻译： 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织 。

    Drug cores for sustained release of therapeutic agents
    2.
    发明申请
    Drug cores for sustained release of therapeutic agents 审中-公开
    用于持续释放治疗剂的药物核心

    公开(公告)号：US20090104243A1

    公开(公告)日：2009-04-23

    申请号：US12231986

    申请日：2008-09-05

    申请人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan, JR. ,  Cary J. Reich

    发明人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan, JR. ,  Cary J. Reich

    IPC分类号： A61K9/14 ,  A61P27/06

    CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F9/00772 ,  A61F2230/0069 ,  A61F2250/0067 ,  A61K31/5575 ,  A61K47/34 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/602 ,  A61L2300/802 ,  Y02A50/395

    摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

    摘要翻译： 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织 。

    DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS
    3.
    发明申请
    DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS 有权
    用于持续释放治疗药物的药物

    公开(公告)号：US20120187594A1

    公开(公告)日：2012-07-26

    申请号：US13367823

    申请日：2012-02-07

    申请人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan ,  Cary J. Reich

    发明人： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene de Juan ,  Cary J. Reich

    IPC分类号： B28B11/12

    CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F9/00772 ,  A61F2230/0069 ,  A61F2250/0067 ,  A61K31/5575 ,  A61K47/34 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/602 ,  A61L2300/802 ,  Y02A50/395

    摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

    摘要翻译： 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织 。

    Lacrimal implants and related methods
    6.
    发明申请
    Lacrimal implants and related methods 有权
    泪液植入及相关方法

    公开(公告)号：US20090264861A1

    公开(公告)日：2009-10-22

    申请号：US12378710

    申请日：2009-02-17

    申请人： Rachna Jain ,  Robert W. Shimizu

    发明人： Rachna Jain ,  Robert W. Shimizu

    IPC分类号： A61F9/00 ,  A61M37/00

    CPC分类号： A61F9/0017 ,  A61B17/12022 ,  A61F9/00772 ,  A61F9/00781 ,  A61F2210/0061 ,  A61K9/0051 ,  A61M29/02 ,  A61M31/00 ,  A61M31/002 ,  A61M2207/00 ,  A61M2210/0612

    摘要： Lacrimal implants and related methods providing secure retention within the lacrimal punctum of an eye are described. The lacrimal implants can comprise a implant body configured for at least partial insertion through the lacrimal punctum and into a lacrimal canaliculus. The implant body can include a deformable retention structure that can be configured to substantially encapsulate an expandable retention element. In some examples, the expandable retention element can include a fluid absorbing material, which can be exposed to fluid such as via a fluid permeable retainer or a fluid permeable aperture. As the fluid absorbing material retains fluid (i.e., upon acceptance of fluid into the retention structure), its size increases and its shape can change to urge one or more portions of the retention structure outward, such as against a wall of the lacrimal canaliculus, thereby securely retaining the lacrimal implant within the punctum.

    摘要翻译： 描述了在泪液泪点内提供牢固保留的泪液植入物和相关方法。 泪液植入物可以包括植入体，其构造成用于至少部分插入通过泪点并进入泪小管。 植入物主体可以包括可变形保持结构，其可被配置为基本上包封可扩张保留元件。 在一些示例中，可扩张保留元件可以包括流体吸收材料，其可以暴露于流体，例如经由流体可渗透保持器或流体可渗透孔。 当流体吸收材料保持流体（即，在将流体接受到保持结构中时），其尺寸增加并且其形状可以改变以将保持结构的一个或多个部分向外推动，例如抵靠泪小管的壁， 从而将泪道植入物牢固地保持在泪点内。

    Injectable sustained release delivery devices
    8.
    发明授权
    Injectable sustained release delivery devices 有权
    可注射持续释放递送装置

    公开(公告)号：US08871241B2

    公开(公告)日：2014-10-28

    申请号：US10714549

    申请日：2003-11-13

    申请人： Kang-Jye Chou ,  Hong Guo ,  Paul Ashton ,  Robert W. Shimizu ,  David A. Watson

    发明人： Kang-Jye Chou ,  Hong Guo ,  Paul Ashton ,  Robert W. Shimizu ,  David A. Watson

    IPC分类号： A61F2/00 ,  A61K9/28 ,  A61K9/00 ,  A61K31/58 ,  A61K45/06 ,  A61K9/24 ,  A61K31/7072 ,  A61K9/20

    CPC分类号： A61K9/0004 ,  A61K9/0024 ,  A61K9/0051 ,  A61K9/0092 ,  A61K9/204 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/284 ,  A61K9/2853 ,  A61K9/2886 ,  A61K31/58 ,  A61K31/7072 ,  A61K45/06 ,  A61K2300/00

    摘要： An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles. The device may be formed by combining at least one polymer, at least one drug, and at least one liquid solvent to form a liquid suspension or solution wherein, upon injection, such suspension or solution under goes a phase change and forms a gel. The configuration may provide for controlled release of the drug(s) for an extended period.

    摘要翻译： 可注射药物递送装置包括含有一种或多种药物的核心和一种或多种聚合物。 芯可以被一个或多个聚合物外层（本文中称为“涂层”，“表皮”或“外层”）包围。 在某些实施方案中，通过挤出或以其它方式预先形成用于药物核心的聚合物皮肤来形成装置。 药物核心可以与皮肤共挤出，或者在皮肤挤出后可以将其插入皮肤中，并可能固化。 在其它实施方案中，药物核心可以涂覆有一种或多种聚合物涂层。 这些技术可以有效地应用于制造具有广泛的药物制剂和皮肤的装置，其可以选择为以适合于使用标准或非标准的注射剂的形式控制药物核心中的药物的释放速率分布和各种其它性质， 标准规格针。 该装置可以通过组合至少一种聚合物，至少一种药物和至少一种液体溶剂以形成液体悬浮液或溶液而形成，其中在注射时，这样的悬浮液或溶液在变相下形成凝胶。 该配置可以提供长时间的药物的控制释放。

    Implantable refillable and ported controlled release drug delivery device
    9.
    发明授权
    Implantable refillable and ported controlled release drug delivery device 有权
    植入式可再充装和移植的控释药物输送装置

    公开(公告)号：US06852106B2

    公开(公告)日：2005-02-08

    申请号：US10013946

    申请日：2001-12-13

    申请人： David A. Watson ,  Robert W. Shimizu ,  Richard LaPorte

    发明人： David A. Watson ,  Robert W. Shimizu ,  Richard LaPorte

    IPC分类号： A61M31/00 ,  A61K9/22 ,  A61L31/00 ,  A61M5/168 ,  A61M5/42 ,  A61M39/02 ,  A61M37/00

    CPC分类号： A61M39/0208 ,  A61M5/16877 ,  A61M5/427 ,  A61M2039/0226 ,  A61M2039/0229 ,  A61M2210/0693

    摘要： An implantable, refillable, rate controlled drug delivery device is disclosed that includes a base structure having at least a first opening and a second opening, the base structure defining a chamber, a septum covering the first opening and configured to substantially prevent leakage from the first opening to an exterior of the device, a drug delivery tube comprising a first and second distal end, wherein the first distal end of the tube communicates with the chamber through the second opening, and at least one rate-limiting permeable membrane disposed across a passage between the base structure and the second distal end of the drug delivery tube, which membrane passively regulates drug delivery. The drug delivery device is used to provide controlled drug delivery to an internal portion of the body and is advantageously leak-proof and does not rely on a pressure differential to drive the drug from the device.

    摘要翻译： 公开了一种可植入的，可再填充的速率控制的药物输送装置，其包括具有至少第一开口和第二开口的基部结构，所述基部结构限定腔室，覆盖所述第一开口的隔膜，并且构造成基本上防止来自所述第一开口 开口到装置的外部，药物输送管包括第一和第二远端，其中管的第一远端通过第二开口与腔室连通，以及至少一个速率限制渗透膜，跨越通道 在药物输送管的基部结构和第二远端之间，该膜被动地调节药物递送。 药物递送装置用于向身体的内部部分提供受控的药物递送，并且有利地是防漏的，并且不依赖于压力来驱动药物从装置。

    Method for treating corneal endothelial wounds
    10.
    发明授权
    Method for treating corneal endothelial wounds 失效
    治疗角膜内皮创伤的方法

    公开(公告)号：US5310728A

    公开(公告)日：1994-05-10

    申请号：US918808

    申请日：1992-07-23

    申请人： Robert W. Shimizu ,  Gregory S. Schultz

    发明人： Robert W. Shimizu ,  Gregory S. Schultz

    IPC分类号： A61K38/18 ,  A61L26/00 ,  A61K37/36

    CPC分类号： A61L26/0066 ,  A61K38/1841 ,  A61L2300/414 ,  Y10S514/912 ,  Y10S514/961 ,  Y10S514/97

    摘要： A method for treating corneal endothelial wounds comprises administering TGF-.alpha. to the region of the wound in an amount sufficient to promote the healing of endothelial cells.TGF-.alpha. advantageously is administered into the anterior chamber during ophthalmic surgical procedures, such as during intra-ocular lens implantation. The TGF-.alpha. preferably is administered as an active ingredient in an ophthalmological viscoelastic composition which improves the residence time of the growth factor in the anterior chamber.

    摘要翻译： 用于治疗角膜内皮创伤的方法包括以足以促进内皮细胞愈合的量给予伤口区域的TGF-α。 TGF-α有利地在眼科手术过程中投入到前房中，例如在眼内晶状体植入期间。 TGF-α优选作为活性成分施用于眼科粘弹性组合物中，其改善生长因子在前房中的停留时间。